May be taken with or without food: For patients w/ decompensated liver disease & lamivudine-refractory patients w/ compensated liver disease, take 2 hr before or 2 hr after meals. In nucleoside naive patients w/ compensated liver disease, may administer w/ meals if necessary.
Lactic acidosis & severe hepatomegaly w/ steatosis; patients w/ risk factors for liver disease. Acute exacerbations of severe hepatitis B in patients who have discontinued therapy. Not recommended for HIV & HBV co-infected patients who are not receiving highly active antiretroviral therapy (HAART). Monitor renal function before & during therapy in liver transplant recipients receiving immunosuppresants eg, cyclosporine or tacrolimus.
J05AF10 - entecavir ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Sign Out
